Emergent BioSolutions (EBS) Misses Q2 EPS by 43c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.55 --0%
Revenue Growth %: -45.6%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -45.6%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($1.06), $0.43 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $337.9 million versus the consensus estimate of $217.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
- BTIG Assumes Essent Group (ESNT) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
